Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease

JAMA Neurology

Volumn 72, Issue 3, 2015, Pages 267-275

  Dorey, Aline ^a,b   Tholance, Yannick ^c,d   Vighetto, Alain ^a   Perret Liaudet, Armand ^a,b   Lachman, Ingolf ^e   Krolak Salmon, Pierre ^a   Wagner, Uta ^e   Struyfs, Hanne ^f   De Deyn, Peter P ^f   El Moualij, Benaissa ^g   Zorzi, Willy ^g   Meyronet, David ^h   Streichenberger, Nathalie ^a,h   Engelborghs, Sebastiaan ^f   Kovacs, Gabor G ⁱ   Quadrio, Isabelle ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b Neurochemistry Unit   (France)

^c UNIVERSITÉ DE LYON   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e Roboscreen GmbH Leipzig   (Germany)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g Institute of Pharmacy CHU   (Belgium)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PRION PROTEIN; PROTEIN 14 3 3; TAU PROTEIN; PRION;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CODON; COHORT ANALYSIS; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ELECTROENCEPHALOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPORADIC CREUTZFELDT JAKOB DISEASE; WESTERN BLOTTING; AGED; CEREBROSPINAL FLUID; CREUTZFELDT-JAKOB SYNDROME; MIDDLE AGED; PRION; VERY ELDERLY;

14-3-3 PROTEINS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COHORT STUDIES; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIONS; RETROSPECTIVE STUDIES;

EID: 84926352143     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.4068     Document Type: Article

References (50)

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
2. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
4. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-627.
5. van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology. 2009;72(12):1056-1061.
6. Koric L, Felician O, Guedj E, et al. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer Dis Assoc Disord. 2010;24(3):278-283.
7. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531-1537.
8. Magnin E, Paquet C, Formaglio M, et al. Increased cerebrospinal fluid tau levels in logopenic variant of Alzheimer's disease. J Alzheimers Dis. 2014;39(3):611-616.
9. Huang N, Marie SK, Livramento JA, Chammas R, Nitrini R. 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology. 2003;61(3):354-357.
10. Jayaratnam S, Khoo AK, Basic D. Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing. 2008;37(4):467-469.
11. Chohan G, Pennington C, Mackenzie JM, et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry. 2010;81(11):1243-1248.
12. Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain. 2012;135(pt 10):3051-3061.
13. Reinwald S, Westner IM, Niedermaier N. Rapidly progressive Alzheimer's disease mimicking Creutzfeldt-Jakob disease. J Neurol. 2004;251(8):1020-1022.
14. Van Everbroeck B, Dobbeleir I, De Waele M, De Deyn P, Martin JJ, Cras P. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol. 2004;251(3):298-304.
15. Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL. Rapidly progressive dementia. Ann Neurol. 2008;64(1):97-108.
16. Bahl JM, Heegaard NH, Falkenhorst G, et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging. 2009;30(11):1834-1841.
17. Josephs KA, Ahlskog JE, Parisi JE, et al. Rapidly progressive neurodegenerative dementias. Arch Neurol. 2009;66(2):201-207.
18. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging. 2010;31(11):1867-1876.
19. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124-1130.
20. Schmidt C, Redyk K, Meissner B, et al. Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord. 2010;29(4):371-378.
21. Struyfs H, Molinuevo JL, Martin JJ, De Deyn PP, Engelborghs S. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. J Alzheimers Dis. 2014;41(3):903-909.
22. WHO. WHO Manual for Surveillance of Human Transmissible Spongiform Encephalopathies, Including Variant Creutzfeldt-Jakob Disease. Geneva, Switzerland: World Health Organization; 2003:90.
23. Quadrio I, Ugnon-Café S, Dupin M, et al. Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues. Lab Invest. 2009;89(4):406-413.
24. Ugnon-Café S, Dorey A, Bilheude JM, et al. Rapid screening and confirmatory methods for biochemical diagnosis of human prion disease. J Virol Methods. 2011;175(2):216-223.
25. Peoc'h K, Manivet P, Beaudry P, et al. Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Hum Mutat. 2000;15(5):482.
26. Seguin J, Formaglio M, Perret-Liaudet A, et al. CSF biomarkers in posterior cortical atrophy. Neurology. 2011;76(21):1782-1788.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revised.Washington, DC; 2000.
28. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(pt 10):2659-2668.
29. Giraud P, Biacabe AG, Chazot G, et al. Increased detection of 14-3-3 protein in cerebrospinal fluid in sporadic Creutzfeldt-Jakob Disease during the disease course. Eur Neurol. 2002;48(4):218-221.
30. Breitling LP, Müller H, Stegmaier C, Kliegel M, Brenner H. Association of prion protein with cognitive functioning in humans. Exp Gerontol. 2012;47(12):919-924.
31. Ferrer I, Puig B, Krupinsk J, Carmona M, Blanco R. Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropathol. 2001;102(2):121-131.
32. Voigtländer T, Klöppel S, Birner P, et al. Marked increase of neuronal prion protein immunoreactivity in Alzheimer's disease and human prion diseases. Acta Neuropathol. 2001;101(5):417-423.
33. Kovacs GG, Budka H. Molecular pathology of human prion diseases. Int J Mol Sci. 2009;10(3):976-999.
34. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38(4):643-648.
35. Meyne F, Gloeckner SF, Ciesielczyk B, et al. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis. 2009;17(4):863-873.
36. Kovacs GG, Seguin J, Quadrio I, et al. Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathol. 2011;121(1):39-57.
37. Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2012;79(6):547-552.
38. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006;67(4):637-643.
39. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2002;58(2):192-197.
40. Coulthart MB, Jansen GH, Olsen E, et al. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurol. 2011;11:133.
41. Tagliapietra M, Zanusso G, Fiorini M, et al. Accuracy of diagnostic criteria for sporadic Creutzfeldt-Jakob disease among rapidly progressive dementia. J Alzheimers Dis. 2013;34(1):231-238.
42. Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8(3):343-347.
43. Skillbäck T, Rosén C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol. 2014;71(4):476-483.
44. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(14):1499-1506.
45. Castellani RJ, Colucci M, Xie Z, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology. 2004;63(3):436-442.
46. Quadrio I, Perret-Liaudet A, Kovacs GG. Molecular diagnosis of human prion disease: expert opinion on medical diagnostics. Expert Opin Med Diagn. 2011;5(4):291-306.
47. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335(13):924-930.
48. McGuire LI, Peden AH, Orrú CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2012;72(2):278-285.
49. Orrú CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014;371(6):519-529.
50. Jackson GS, Burk-Rafel J, Edgeworth JA, et al. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. JAMA Neurol. 2014;71(4):421-428.